Shanghai Upbio Tech Co.,Ltd（expird）
Free supplier Enterprise Certification
- Free
supplier - 12th
years
Free supplier Enterprise Certification
Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Lab/Research institutions
CAS NO.30516-87-1
99%(1.0000-100.0000)Gram
.Detailed product information:
Product Name: Zidovudine
Chemical Name:
1-[(2R,4S,5S)-4-Azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methylpyrimidine-2,4-(1H,3H)-dione
CAS: 30516-87-1
Molecular Formula:C10H13N5O4
Molecular Weight: 267.25
Specification: USP/EP
Structural Formula:
2.Typical specification of Zidovudine:
|
TESTS |
STANDARDS |
|
APPEARANCE |
WHITE TO YELLOWISH CRYSTALLINE POWDER |
|
SOLUBILITY |
SPARINGLY SOLUBLE IN WATER,FREELY SOLUBLE IN METHANOL, SOLUBLE IN ETHANOL |
|
IDENTIFICATION |
A: IR B: HPCL |
|
MELTING POINT |
118°CMIN |
|
SPECIFIC ROTATION |
+60.5º TO 63.0º |
|
WATER |
1.0%MAX |
|
RESIDUE ON IGNITION |
0.25%MAX |
|
TOTAL IMPURITIES |
1.0%MAX |
|
HEAVY METALS |
10PPM MAX |
|
ASSAY |
97-102.0% |
Usage:
Zidovudine is the first U.S. government-approved treatment for HIV therapy, prescribed under the name Retrovir. Zidovudine was the first breakthrough in AIDS therapy, significantly reducing the replication of the virus in patients and leading to clinical and immunologic improvements. It can also be used to prevent HIV transmission, such as from mother to child during the period of birth or after a needle stick. Used by itself in HIV-infected patients, Zidovudine safely slows HIV replication in patients, but generally does not stop it entirely. This may allow HIV to become Zidovudine-resistant over time, and for this reason, Zidovudine is usually used in conjunction with the other anti-HIV drugs in combination therapy called highly active antiretroviral therapy (HAART).
Molecular Formula: C10H13N5O4
Molecular Weight: 267.25
Specification: USP
Usage:
Zidovudine is the first U.S. government-approved treatment for HIV therapy, prescribed under the name Retrovir. Zidovudine was the first breakthrough in AIDS therapy, significantly reducing the replication of the virus in patients and leading to clinical and immunologic improvements. It can also be used to prevent HIV transmission, such as from mother to child during the period of birth or after a needle stick. Used by itself in HIV-infected patients, Zidovudine safely slows HIV replication in patients, but generally does not stop it entirely. This may allow HIV to become Zidovudine-resistant over time, and for this reason, Zidovudine is usually used in conjunction with the other anti-HIV drugs in combination therapy called highly active antiretroviral therapy (HAART).